Welcome to the official InxMed website


InxMed translates unmet medical need into breakthrough product. Rooted in disease biology driven translational research, we develop innovative therapies targeting essential survival mechanism of tumors. 


InxMed have invented a highly differentiable portfolio of novel therapeutics against full nodes in tumor defense, expanding from cell membrane to nucleus, with modalities of small molecule, antibody and ADC. The target breadth and therapeutic modalities  enable us to pursue fundamental solutions to improved efficacy and prolong survival in patients with a variety  of cancer types.



Rationalized combo is a must to win the battle against cancers.  InxMed aims to invent regimen which is highly efficacious but safer. It is only possible to achieve such goal via partnership. We actively seek  co-development and strategic business development opportunities, especially  clinical combination and licensing of inhibitors of RAS pathway and ADCs. We aim to invent revolutionary, breakthrough therapies based on deep insights of underlying disease biology.



InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

NANJING, China, June 3, 2024 -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, today announced results from the Phase Ib/II clinical trial of ifebemtinib, the company's focal adhesion kinase (FAK) inhibitor, in combination with garsorasib, a specific inhibitor of the KRAS G12C mutation, for the first-line treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation.

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

Nanjing, China, Dec 20, 2023 -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload platform from Escugen for the development of the next generation tumor-associated antigens (TAAs) targeting ADCs.  

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 23, 2023 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in platinum-resistant recurrent ovarian cancer (PROC)and triple-negative breast cancer(TNBC)has been presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid,Spain.

BioWorld:Inxmed raises $50M to develop cancer therapy in the US, China

Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.

Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009

In June 2019, New England magazine published the major research achievement of Tu youyou's team - "artemisinin resistance" treatment response plan. This is an important achievement of China in the field of global drug R & D. Benchmarking international, China's R & D of innovative drugs has attracted worldwide attention.

Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence

Dr. Wang Zaiqi will attend the global clinical research and development failure and success case analysis, the 96th activity of the same freehand brushwork forum for the third time, and make a special report - "the experience of using anti-PD-1 combined chemotherapy drugs in gastric cancer chemotherapy - excellent early trial data and disappointing phase 3 results. What have we learned?"

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world



Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing


Follow Us:

CopyRight © 2022 InxMed All Rights Reserved.

Powered by: 300.cn | SEO